Targeted-sequence of normal urothelium and tumor of patients with non-muscle invasive bladder cancer | Scientific Reports – Nature.com

Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759767 (1990).

CAS Article Google Scholar

Lee-Six, H. et al. The landscape of somatic mutation in normal colorectal epithelial cells. Nature 574, 532537 (2019).

ADS CAS Article Google Scholar

Brunner, S. F. et al. Somatic mutations and clonal dynamics in healthy and cirrhotic human liver. Nature 574, 538542 (2019).

ADS CAS Article Google Scholar

Martincorena, I. et al. Somatic mutant clones colonize the human esophagus with age. Science 362, 911917 (2018).

ADS CAS Article Google Scholar

Martincorena, I. et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348, 8806 (2015).

ADS CAS Article Google Scholar

Yoshida, K. et al. Tobacco smoking and somatic mutations in human bronchial epithelium. Nature 578, 266272 (2020).

ADS CAS Article Google Scholar

Lee-Six, H. et al. Population dynamics of normal human blood inferred from somatic mutations. Nature 561, 473478 (2018).

ADS CAS Article Google Scholar

Li, R. et al. Macroscopic somatic clonal expansion in morphologically normal human urothelium. Science 370, 8289 (2020).

ADS CAS Article Google Scholar

Lawson, A. R. J. et al. Extensive heterogeneity in somatic mutation and selection in the human bladder. Science 370, 7582 (2020).

ADS CAS Article Google Scholar

van Oers, J. M. et al. Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. Int. J Cancer 119, 12121215 (2006).

Article Google Scholar

Hartmann, A. et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res. 62, 809818 (2002).

CAS PubMed Google Scholar

Knowles, M. A. & Hurst, C. D. Molecular biology of bladder cancer: New insights into pathogenesis and clinical diversity. Nat. Rev. Cancer 15, 2541 (2015).

CAS Article Google Scholar

Majewski, T. et al. Whole-organ genomic characterization of mucosal field effects initiating bladder carcinogenesis. Cell Rep. 26, 22412256 (2019).

CAS Article Google Scholar

Borah, S. et al. Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer. Science 347, 100610 (2015).

ADS CAS Article Google Scholar

Hayashi, Y. et al. TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer. Mol. Oncol. 14, 23752383 (2020).

CAS Article Google Scholar

Hayashi, Y. et al. Telomerase reverse transcriptase promoter mutation in tumorigenesis of bladder cancer: Evolutionary trajectory by algorithmic inference from cross-sectional data. Int. J. Urol. 28, 774776 (2021).

CAS Article Google Scholar

Amin, M. B. et al. AJCC Cancer Staging Manual, eighth ed. (2017).

Moch, H., Humphrey, P. A., Ulbright, T. M.& Reuter, V. E. International Agency for Research on Cancer: WHO Classification of Tumours of Urinary System and Male Genital Organs, fourth ed. (2016).

Hayashi, Y. et al. Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma. Cancer Sci. 110, 17711779 (2019).

CAS Article Google Scholar

Sakai, K. et al. Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status. Cancer Lett. 405, 2228 (2017).

ADS CAS Article Google Scholar

Noguchi, T. et al. Comprehensive gene mutation profiling of circulating tumor DNA in ovarian cancer: Its pathological and prognostic impact. Cancers (Basel) 12, 3382 (2020).

CAS Article Google Scholar

Ploussard, G. et al. Prognostic value of loss of heterozygosity at chromosome 9p in non-muscle-invasive bladder cancer. Urology 76, 513 (2010).

Article Google Scholar

Krger, S., Mahnken, A., Kausch, I. & Feller, A. C. P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma. Eur. Urol. 47, 463467 (2005).

Article Google Scholar

Bartoletti, R. et al. Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer. J. Surg. Res. 143, 422427 (2007).

CAS Article Google Scholar

Castillo-Martin, M., Domingo-Domenech, J., Karni-Schmidt, O., Matos, T. & Cordon-Cardo, C. Molecular pathways of urothelial development and bladder tumorigenesis. Urol. Oncol. 28, 401408 (2010).

CAS Article Google Scholar

Killela, P. J. et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc. Natl. Acad. Sci. U. S. A. 110, 60216 (2013).

ADS CAS Article Google Scholar

Huang, F. W. et al. Highly recurrent TERT promoter mutations in human melanoma. Science 339, 957959 (2013).

ADS CAS Article Google Scholar

Rodriguez, P. M. D. C. et al. Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder. Virchows Arch. 471, 761767 (2017).

Article Google Scholar

Nguyen, D. et al. High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma. Virchows Arch. 469, 427434 (2016).

CAS Article Google Scholar

Cowan, M. L. et al. Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder. Hum. Pathol. 53, 813 (2016).

CAS Article Google Scholar

Cowan, M. et al. High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder. Mod. Pathol. 29, 511515 (2016).

CAS Article Google Scholar

Zheng, X. et al. High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins. J. Hematol. Oncol. 7, 47. https://doi.org/10.1186/s13045-014-0047-7 (2014).

CAS Article PubMed PubMed Central Google Scholar

Palsgrove, D. N. et al. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations. Hum. Pathol. 85, 19 (2019).

CAS Article Google Scholar

Chiba, K. et al. Mutations in the promoter of the telomerase gene TERT contribute to tumorigenesis by a two-step mechanism. Science 357, 14161420 (2017).

ADS CAS Article Google Scholar

Pietzak, E. J. et al. Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets. Eur. Urol. 72, 952959 (2017).

CAS Article Google Scholar

Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 174, 1033 (2018).

CAS Article Google Scholar

Nabel, E. G. CDKs and CKIs: Molecular targets for tissue remodelling. Nat. Rev. Drug Discov. 1, 587598 (2002).

CAS Article Google Scholar

Witcher, M. & Emerson, B. M. Epigenetic silencing of the p16(INK4a) tumor suppressor is associated with loss of CTCF binding and a chromatin boundary. Mol. Cell. 34, 271284 (2009).

CAS Article Google Scholar

Petitjean, A., Achatz, M. I., Borresen-Dale, A. L., Hainaut, P. & Olivier, M. TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes. Oncogene 26, 21572165 (2007).

CAS Article Google Scholar

Springer, S. U. et al. Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. Elife 7, e32143. https://doi.org/10.7554/eLife.32143 (2018).

Article PubMed PubMed Central Google Scholar

Hayashi, Y. et al. Clinical significance of hotspot mutation analysis of urinary cell-free DNA in urothelial bladder cancer. Front. Oncol. 10, 755. https://doi.org/10.3389/fonc.2020.00755 (2020).

Article PubMed PubMed Central Google Scholar

View original post here:
Targeted-sequence of normal urothelium and tumor of patients with non-muscle invasive bladder cancer | Scientific Reports - Nature.com